China May Modify Single-Pricing Policy For Off-Patent Drugs
This article was originally published in PharmAsia News
Executive Summary
China's National Development and Reform Commission has requested related organizations to conduct a special investigation on the pricing and application quantity of off-patent drugs and generics, showing NDRC's intention to narrow the huge gap between both types of drugs. China's price policy allows off-patent drugs to enjoy a premium of 35 and 30 percent over GMP-produced generic injections and other formulations, respectively. However, industry sources disclose that off-patent drugs, of which overseas firms and joint ventures have the lion's share, are actually double to triple the price of generics. Many local pharmaceutical manufacturers accuse the policy of giving preferential treatment to foreign companies and joint ventures, at the expense of domestic enterprises. (Click here for more - Chinese Language)
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.